Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04119453 · ClinicalTrials.gov registry record · Phase 2
A Study to Evaluate the Efficacy and Safety of Rivoceranib in Participants With Recurrent or Metastatic Adenoid Cystic Carcinoma (ACC)
A Phase 2 study, sponsored by Elevar Therapeutics.
- Terminated
- Registry status
- Phase 2
- Development phase
- 80
- Enrollment target
NCT04119453 is a Phase 2 study that was terminated before completion, run by Elevar Therapeutics. The registered enrollment target is 80 participants.
The verdict
NCT04119453, a Phase 2 study, was terminated before completion, sponsored by Elevar Therapeutics.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 80 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the efficacy and safety of rivoceranib in adult participants with recurrent or metastatic ACC. All participants may remain on treatment until occurrence of disease progression, unacceptable toxicity, death, the withdrawal of consent from treatment, lost to follow-up or study termination by the Sponsor. When a participant discontinues rivoceranib for any reason, the participant will enter the 24 month survival follow up period until withdrawal of consent from the study, lost to follow up, end of the study or death, whichever occurs earlier. The maximum duration of the study is estimated to be 48 months and includes screening, treatment, and follow-up phases.
Interventions
- DRUG Rivoceranib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 80 participants |
| Start Date | 2020-01-22 |
| Est. Completion | 2023-06-28 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04119453
The ClinicalTrials.gov registry entry for NCT04119453 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 80 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Elevar Therapeutics, which has 8 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Rivoceranib is the first listed.
NCT04119453 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04119453 about?
NCT04119453 is a clinical study titled "A Study to Evaluate the Efficacy and Safety of Rivoceranib in Participants With Recurrent or Metastatic Adenoid Cystic Carcinoma (ACC)". The purpose of this study is to evaluate the efficacy and safety of rivoceranib in adult participants with recurrent or metastatic ACC. All participants may remain on treatment until occurrence of disease progression, unacceptable toxicity, death, the withdrawal of consent from treatment, lost to fo...
What is the current status of trial NCT04119453?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 80 participants. The study started on 2020-01-22. Estimated completion is 2023-06-28.
What interventions are being tested in trial NCT04119453?
The interventions under investigation include: Rivoceranib (DRUG).
Who is sponsoring clinical trial NCT04119453?
This trial is sponsored by Elevar Therapeutics, which has 8 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.